An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines

British Journal of Cancer

Volumn 90, Issue 2, 2004, Pages 542-548

  Sangar, V K ^a,b,c   Cowan, R ^b   Margison, G P ^a   Hendry, J H ^a,d   Clarke, N W ^b,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

Bladder; Gemcitabine; Radiation

Indexed keywords

GEMCITABINE;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CLONE; CELL KILLING; CELL MUTANT; COLONY FORMATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANTIMETABOLITES, ANTINEOPLASTIC; COLONY-FORMING UNITS ASSAY; DEOXYCYTIDINE; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 1342344000     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601538     Document Type: Article

References (33)

1. Banasiak D, Barneston AR, Odell RA, Mameghan H, Russell PJ (1999) Comparison between the clonogenic, MT and SRB assay for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Invest 7: 77-85
2. Blandy JP, England HR, Evans SJW, Hope-Stone HF, Mair GMM, Mantell BS, Oliver RT, Paris AMI, Risdon RA (1980) T3 bladder cancer - the case for salvage cystectomy. Br J Urol 52: 506-510
3. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, Ubezio P (2001) Cell cycle effects of gemcitabine. Int J Cancer 93: 401-408
4. Chen M, Hough AM, Lawrence TS (2000) The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 45: 369-374
5. Fechner G, Perabo FGE, Schimdt DH, Haase L, Ludwig HE, Schueller H, Blatter J, Muller SC, Albers P (2003) Preclinical evaluation of radiosensitising effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. Urology 61(2): 468-473
6. Fields MT, Eisbruch A, Normolle D, Orfall A, Davis MA, Pu AT, Lawrence TS (2000) Radiosensitization produced in vivo by once vs twice weekly 2,2-difluoro-2-deoxycytidine (gemcitabine). Int J Radial Oncol Biol Phys 47(3): 785-791
7. Fossa SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S (1993) Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72(10): 3036-3043
8. Gregoire V, Beauduin M, Bruniaux M, De Coster B, Ocatave Prignot M, Scalliet P (1998) Radiosensitization of mouse sarcoma cells by fludarabine or gemcitabine, two nucleoside analogues, is not mediated by an increased induction or repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 73(5): 51-520
9. Gregoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave Prignot M, Scalliet P (2002) Role of deoxycytidine kinase activity in gemcitabine radioenhancement in mice and human cell lines in vitro. Radiother Oncol 63: 329-338
10. Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, Hope-Stone HF, Oliver RT, Blandy JP (1988) Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 62(4): 343-346
11. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ (1997) Enhancement of radiation induced regrowth delay by gemcitabine in a human tumour xenograft model. Radial Oncol Invest 5: 62-71
12. Kassem HSh, Sangar V, Cowan R, Clarke N, Margison GP (2002) A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 101(5): 454-460
13. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2,2-difluoro-2-deoxycytidine. Int J Radiat Biol Phys 34(4): 867-872
14. Lawrence TS, Davis MA, Hough A, Rehemtulla A (2001) The role of apoptosis in 2,2-difluoro-2-deoxycytidine (gemcitabine) mediated radiosensitization. Clin Cancer Res 7: 314-319
15. Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman KW, Ang KK (1999) Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44(5): 1125-1135
16. McMillan TJ, Holmes A (1991) The isolation and partial characterization of a radiation sensitive clone of a human bladder carcinoma cell line. Radiat Res 128: 301-305
17. Merlin T, Brander G, Hess RD (1998) Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. Int J Oncol 12: 1007-1016
18. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelmann W (1999) Enhancement of tumour radioresponse in vitro by gemcitabine. Cancer Res 59: 107-114
19. Office of Population Censuses and Surveys (1995) Cancer Statistics Registrations. London: HMSO
20. Ostruszka LJ, Shewach DS (2000) The role of cell cycle progression in radiosensitization by 2,2-difluoro-2-deoxycytidine. Cancer Res 60: 6080-6088
21. Pacini S, Milano F, Pinzani P, Pazzagli M, Gulisano M, Ruggiero M, Casamassima F (1999) Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity. Tumori 85: 503-507
22. Pattaranutaporn P, Thirapakawong C, Chasilpa Y, Therasakvichya S, Leumwannontachai N, Thephamongkhol K (2001) Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIb cervical carcinoma. Gynaecol Oncol 81: 404-407
23. Pauwels B, Korst AEC, de Pooter CMJ, Lambrechts HAJ, Pattyn GGO, Lardon F, Vermorken JB (2003) The radiosensitising eefcet of gemcitabine and the influence of the rescue agent amifostine in vitro. Eur J Cancer 39: 838-846
24. Price P, McMillan TJ (1990) Use of the Tetrazolium assay in measuring the response of human tumour cells to ionising radiation. Cancer Res 50: 1392-1396
25. Robinson BW, Shewach DS (2001) Radiosensitization by gemcitabine in p53 wild type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 7: 2581-2589
26. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS (1994) Metabolism of 2,2-difluoro-2-deoxycytidine and radiation sensitisation of human colon carcinoma cells. Cancer Res 54: 3218-3223
27. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145(3): 459-464 discussion 464-467
28. Slavotinek A, McMillan TJ, Steel CM (1994) Measurement of radiation survival using MTT assay. Eur J Cancer 30A(9): 1376-1382
29. Stadler WM, Kuzel T, Rath B, Raghavan D, Dorr FA (1997) Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15(11): 3394-3398
30. Steel GG (1997) Clonogenic cells and the concept of cell survival. Basic Clinical Radiobiology, Chapter 6, pp 40-51, Arnold, New York, USA
31. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and ciplatin in advanced or metastatic bladder cancer: results of a large randomised multinational multicentre phase III study. J Clin Oncol 17(17): 3068-3077
32. Van Putten JWG, Greon HJM, Smid K, Peters GJ, Kampinga HH (2001) End joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 61: 1585-1591
33. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PWT, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adencarcinoma. Clin Cancer Res 7: 2246-2253